Nikhil Pillai
Overview
Explore the profile of Nikhil Pillai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patidar K, Pillai N, Dhakal S, Avery L, Mavroudis P
Sci Rep
. 2025 Feb;
15(1):4198.
PMID: 39905178
Development of antibodies often begins with the assessment and optimization of their physicochemical properties, and their efficient engagement with the target of interest. Decisions at the early optimization stage are...
2.
Pillai N, Abos A, Teutonico D, Mavroudis P
Clin Transl Sci
. 2024 May;
17(5):e13824.
PMID: 38752574
Accurate prediction of a new compound's pharmacokinetic (PK) profile is pivotal for the success of drug discovery programs. An initial assessment of PK in preclinical species and humans is typically...
3.
Patidar K, Pillai N, Dhakal S, Avery L, Mavroudis P
J Pharmacokinet Pharmacodyn
. 2024 Feb;
51(5):477-492.
PMID: 38400996
Protein therapeutics have revolutionized the treatment of a wide range of diseases. While they have distinct physicochemical characteristics that influence their absorption, distribution, metabolism, and excretion (ADME) properties, the relationship...
4.
van Hazendonk L, Pinto A, Arapov K, Pillai N, Beurskens M, Teunissen J, et al.
Chem Mater
. 2022 Sep;
34(17):8031-8042.
PMID: 36117880
Skin-compatible printed stretchable conductors that combine a low gauge factor with a high durability over many strain cycles are still a great challenge. Here, a graphene nanoplatelet-based colloidal ink utilizing...
5.
Mavroudis P, Pillai N, Wang Q, Pouzin C, Greene B, Fretland J
CPT Pharmacometrics Syst Pharmacol
. 2022 Aug;
11(11):1485-1496.
PMID: 36004727
Osteogenesis imperfecta (OI) is a heterogeneous group of inherited bone dysplasias characterized by reduced skeletal mass and bone fragility. Although the primary manifestation of the disease involves the skeleton, OI...
6.
Pillai N, Dasgupta A, Sudsakorn S, Fretland J, Mavroudis P
Drug Discov Today
. 2022 Apr;
27(8):2209-2215.
PMID: 35364270
Machine learning (ML) approaches have been widely adopted within the early stages of the drug discovery process, particularly within the context of small-molecule drug candidates. Despite this, the use of...
7.
Ismail M, Sale M, Yu Y, Pillai N, Liu S, Pflug B, et al.
J Pharmacokinet Pharmacodyn
. 2021 Oct;
49(2):243-256.
PMID: 34604941
The current approach to selection of a population PK/PD model is inherently flawed as it fails to account for interactions between structural, covariate, and statistical parameters. Further, the current approach...
8.
Ozawa C, Bies R, Pillai N, Suzuki T, Mimura M, Uchida H
J Clin Psychopharmacol
. 2019 Jun;
39(4):329-335.
PMID: 31188232
Purpose/background: Patients with schizophrenia as well as their psychiatrists are hesitant to reduce the antipsychotic dose in fear of relapse. To overcome such dilemmas, we developed models to individually calculate...
9.
Pillai N, Schwartz S, Ho T, Dokoumetzidis A, Bies R, Freedman I
J Pharmacokinet Pharmacodyn
. 2019 Apr;
46(2):193-210.
PMID: 30929120
Bridging fundamental approaches to model optimization for pharmacometricians, systems pharmacologists and statisticians is a critical issue. These fields rely primarily on Maximum Likelihood and Extended Least Squares metrics with iterative...
10.
Pillai N, Craig M, Dokoumetzidis A, Schwartz S, Bies R, Freedman I
Prog Biophys Mol Biol
. 2018 Jun;
139:23-30.
PMID: 29928905
In mathematical pharmacology, models are constructed to confer a robust method for optimizing treatment. The predictive capability of pharmacological models depends heavily on the ability to track the system and...